Qiagen N.V. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 22 Fair Values set on narratives written by author
QGEN Community Narratives
QGEN: Future Results Will Depend On Automation And Gradual Sentiment Recovery
Latent Tuberculosis And Research Pressures Will Constrain Progress Yet Long-Term Prospects Remain Intact
Latent TB Testing Expansion And Automation Will Support Stronger Long Term Prospects
QGEN: Future Results Will Depend On Automation And Gradual Sentiment Recovery
View narrativeLatent Tuberculosis And Research Pressures Will Constrain Progress Yet Long-Term Prospects Remain Intact
View narrativeLatent TB Testing Expansion And Automation Will Support Stronger Long Term Prospects
View narrativeTrending Discussion
No trending discussion available.
Recently Updated Narratives
QGEN: Pipeline Progress And Takeover Interest Will Shape Medium Term Outlook
QGEN: Post Pandemic Testing And Takeover Interest Will Shape Oncology And Diagnostics Outlook
QGEN: Takeover Interest Will Drive Reassessment Of Core Life Science Franchise
Snowflake Analysis
Qiagen N.V. Key Details
About QGEN
- Founded
- 1984
- Employees
- 5500
- CEO
- Website
View website
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.